Loading Piramal Pharma…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 2,270 | 2,752 | 2,140 | 1,934 | 2,754 |
| Operating profit | -28 | 242 | -17 | -91 | 318 |
| Operating margin | -1.2% | 8.8% | -0.8% | -4.7% | 11.6% |
| Net profit | -69 | -9 | -136 | -82 | 154 |
| Net margin | -3.1% | -0.3% | -6.4% | -4.2% | 5.6% |
| EPS (₹) | -0.52 | -0.07 | -1.03 | -0.62 | 1.16 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 8,759 | 9,061 | 8,106 | 7,032 |
| Operating profit | 155 | 679 | 462 | -48 |
| Operating margin | 1.8% | 7.5% | 5.7% | -0.7% |
| Net profit | -326 | 91 | 18 | -186 |
| Net margin | -3.7% | 1.0% | 0.2% | -2.7% |
| EPS (₹) | -2.46 | 0.69 | 0.14 | -1.54 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 17,965 | 15,678 | 15,312 | 14,523 |
| Total liabilities | 9,802 | 7,552 | 7,400 | 7,749 |
| Shareholders’ equity | 8,163 | 8,125 | 7,911 | 6,774 |
| Total debt | 5,675 | 4,856 | 4,710 | 5,637 |
| Cash & equivalents | 1,200 | 369 | 357 | 196 |
| Debt / equity | 0.70 | 0.60 | 0.60 | 0.83 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 1,653 | 892 | 1,005 | 484 |
| Capital expenditure | -890 | -664 | -712 | -965 |
| Free cash flow | 763 | 228 | 293 | -481 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | -4.0% | 1.1% | 0.2% | -2.8% |
| Return on assets | -1.8% | 0.6% | 0.1% | -1.3% |
| Net margin | -3.7% | 1.0% | 0.2% | -2.7% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for PPLPHARMA. Finnhub coverage is limited for some India-listed stocks.